Literature DB >> 25082860

p53 at the crossroads of MPN treatment.

Isabelle Plo1.   

Abstract

In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25082860      PMCID： PMC4118478          DOI： 10.1182/blood-2014-06-579623

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Authors:  S Hasan; B Cassinat; N Droin; J P Le Couedic; F Favale; B Monte-Mor; C Lacout; M Fontenay; C Dosquet; C Chomienne; E Solary; J L Villeval; N Casadevall; J J Kiladjian; W Vainchenker; I Plo
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

2.  p53 lesions in leukemic transformation.

Authors:  Ashot Harutyunyan; Thorsten Klampfl; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

3.  The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Authors:  Min Lu; Lijuan Xia; Yan Li; Xiaoli Wang; Ronald Hoffman
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

Review 4.  The renaissance of interferon therapy for the treatment of myeloid malignancies.

Authors:  Jean-Jacques Kiladjian; Ruben A Mesa; Ronald Hoffman
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

5.  JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.

Authors:  M Nakatake; B Monte-Mor; N Debili; N Casadevall; V Ribrag; E Solary; W Vainchenker; I Plo
Journal:  Oncogene       Date:  2011-07-25       Impact factor: 9.867

6.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

7.  JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Authors:  Salma Hasan; Catherine Lacout; Caroline Marty; Marie Cuingnet; Eric Solary; William Vainchenker; Jean-Luc Villeval
Journal:  Blood       Date:  2013-07-17       Impact factor: 22.113

8.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

9.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Authors:  Alfonso Quintás-Cardama; Omar Abdel-Wahab; Taghi Manshouri; Outi Kilpivaara; Jorge Cortes; Anne-Laure Roupie; Su-Jiang Zhang; David Harris; Zeev Estrov; Hagop Kantarjian; Ross L Levine; Srdan Verstovsek
Journal:  Blood       Date:  2013-06-19       Impact factor: 22.113

10.  Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons.

Authors:  Eric M Pietras; Ranjani Lakshminarasimhan; Jose-Marc Techner; Sarah Fong; Johanna Flach; Mikhail Binnewies; Emmanuelle Passegué
Journal:  J Exp Med       Date:  2014-02-03       Impact factor: 14.307
  10 in total
  2 in total

1.  Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells.

Authors:  Min Lu; Lijuan Xia; Nada Elmansy; Cara Clementelli; Douglas Tremblay; Ronald Hoffman
Journal:  Leukemia       Date:  2021-10-12       Impact factor: 11.528

Review 2.  Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Authors:  Maria Teresa Bochicchio; Valeria Di Battista; Pietro Poggio; Giovanna Carrà; Alessandro Morotti; Mara Brancaccio; Alessandro Lucchesi
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.